Drug intelligence / Profile preview

BPI Protacs

Development stage: Preclinical
Lead developer: Beta Pharma Technologies
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

BPI Protacs refers to a targeted protein degradation (TPD) program and platform developed by Beta Pharma Technologies. These therapeutic candidates are designed as proteolysis-targeting chimeras (PROTACs), which are heterobifunctional small molecules that simultaneously bind a disease-causing target protein and an E3 ubiquitin ligase. This recruitment facilitates the polyubiquitination of the target protein, marking it for selective degradation by the 26S proteasome. The BPI Protacs program is currently in the preclinical stage of development, primarily focused on the treatment of various solid tumors.

Beyond the preview

Go deeper on BPI Protacs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPI Protacs.

Explore the full profile